Franklin Biotechnology Discovery Fund A(acc)USD

Register to Unlock Ratings
Performance History30/09/2021
Growth of 1,000 (GBP) Advanced Graph
Franklin Biotechnology Discovery Fund A(acc)USD
Fund6.8-11.128.423.6-8.1
+/-Cat-3.5-3.18.2-2.4-7.6
+/-B’mrk-4.3-7.98.11.1-16.9
 
Key Stats
NAV
19/10/2021
 USD 39.70
Day Change 0.21%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU0109394709
Fund Size (Mil)
30/09/2021
 USD 2351.23
Share Class Size (Mil)
30/09/2021
 USD 1774.32
Max Initial Charge 5.75%
Ongoing Charge
24/01/2021
  1.83%
Morningstar Research
Analyst Report

A capable trio leads Franklin Biotechnology Discovery, but limited resources constrain the extent to which the managers can apply their process, limiting the fund to a Morningstar Analyst Rating of Neutral.Three managers provide solid expertise,...

Click here to read this analyst report on the underlying fund.
Morningstar Pillars
PeopleAverage
ParentAverage
ProcessAverage
Performance
Price
Investment Objective: Franklin Biotechnology Discovery Fund A(acc)USD
The Fund invests principally in equity securities of biotechnology companies and discovery research firms located in the US and other countries and to a lesser extent in debt securities of any type of issuers worldwide. For the Fund’s investment purposes, a biotechnology company is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities based on the company’s most recent fiscal year. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture.
Returns
Trailing Returns (GBP)19/10/2021
YTD-12.78
3 Years Annualised6.73
5 Years Annualised5.85
10 Years Annualised15.89
12 Month Yield 0.00
Management
Manager Name
Start Date
Evan McCulloch
01/11/2000
Wendy Lam
01/09/2018
Click here to see others
Inception Date
03/04/2000
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Franklin Biotechnology Discovery Fund A(acc)USD30/09/2021
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.690.0095.69
Bond0.210.000.21
Property0.000.000.00
Cash3.710.003.71
Other0.400.000.40
Top 5 Regions%
United States93.34
Asia - Emerging2.88
United Kingdom1.25
Canada1.24
Europe - ex Euro0.90
Top 5 Sectors%
Healthcare98.34
Financial Services1.66
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare5.62
Amgen IncHealthcareHealthcare4.78
Gilead Sciences IncHealthcareHealthcare4.64
Illumina IncHealthcareHealthcare4.32
Moderna IncHealthcareHealthcare4.31
Franklin Biotechnology Discovery Fund A(acc)USD

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)